Table 2.
Recipient Characteristics. Demographic and Clinical Characteristics of Orthotopic Heart Transplant Recipients, Stratified by HIV Status of Recipient, January 2005 – June 2019
| Variable | HIV - recipient | HIV + recipient | p-value |
|---|---|---|---|
| (n=29,848) | (n=75) | ||
| Male sex | 22,114 (74.1%) | 60 (80.0%) | 0.301 |
| Sex mismatch | 4,165 (14.0%) | 13 (17.3%) | 0.499 |
| Age (median years, IQR) | 56 (46–63) | 50 (38–61) | 0.004 |
| BMI (median kg/m2, IQR) | 27.0 (23.7–30.6) | 27.3 (24.4–30.0) | 0.788 |
| Ethnicity | <0.001 | ||
| White | 19,817 (66.4%) | 31 (41.3%) | |
| Black | 6,237 (20.9%) | 35 (46.7%) | |
| Hispanic | 2,456 (8.2%) | 7 (9.3%) | |
| Other | 1,338 (4.5%) | 2 (2.7%) | |
| Recipient history | |||
| Diabetes | 8,277 (27.7%) | 15 (20.0%) | 0.172 |
| Malignancy | 2,339 (7.8%) | 4 (5.3%) | 0.555 |
| Cerebrovascular disease | 1,629 (5.5%) | 3 (4.0%) | 0.764 |
| Heart failure etiology | 0.003 | ||
| Ischemic | 9,505 (31.8%) | 14 (18.7%) | |
| Non-ischemic dilated | 14,512 (48.6%) | 51 (68.0%) | |
| Other | 5,831 (19.5%) | 10 (13.3%) | |
| Recipient creatinine (median mg/dL, IQR) | 1.2 (1.0–1.5) | 1.2 (1.0–1.5) | 0.739 |
| Recipient bilirubin (median mg/dL, IQR) | 0.7 (0.5–1.2) | 0.6 (0.4–1.1) | 0.088 |
| Pre-transplant status | 0.262 | ||
| Intensive care unit | 9,159 (30.7%) | 19 (25.3%) | |
| Hospitalized (non-ICU) | 4,823 (16.2%) | 17 (22.7%) | |
| Not hospitalized | 15,863 (53.2%) | 39 (52.0%) | |
| Medical therapy | |||
| IV antibiotics in two weeks before transplant | 3,087 (10.3%) | 9 (12.0%) | 0.779 |
| IV inotropes prior to transplant | 11,470 (38.4%) | 20 (26.7%) | 0.049 |
| Ventilator support prior to transplant | 440 (1.5%) | 4 (5.3%) | 0.022 |
| Durable LVAD support prior to transplant | 10,425 (34.9%) | 29 (38.7%) | 0.577 |
| Temporary MCS prior to transplant | 3,692 (12.4%) | 17 (22.7%) | 0.011 |
| IABP | 2,985 (10.0%) | 12 (16.0%) | 0.125 |
| ECMO | 421 (1.4%) | 2 (2.7%) | 0.667 |
| Temporary VAD | 520 (1.7%) | 4 (5.3%) | 0.054 |
| ABO blood type | 0.591 | ||
| A | 12,071 (40.4%) | 29 (38.7%) | |
| B | 4,445 (14.9%) | 15 (20.0%) | |
| AB | 1,659 (5.6%) | 5 (6.7%) | |
| O | 11,673 (39.1%) | 26 (34.7%) | |
| Days on waitlist (median days, IQR) | 90 (26–258) | 87 (33–227) | 0.683 |
| Waitlist status at transplant | - | ||
| Old 1A | 16,414 (55.0%) | 42 (56.0%) | |
| Old 1B | 9,418 (31.6%) | 16 (21.3%) | |
| Old 2 | 2,029 (6.8%) | 3 (4.0%) | |
| New 1 | 168 (0.6%) | 1 (1.3%) | |
| New 2 | 887 (3.0%) | 7 (9.3%) | |
| New 3 | 504 (1.7%) | 1 (1.3%) | |
| New 4 | 352 (1.2%) | 3 (4.0%) | |
| New 5 | 8 (0.0%) | - | |
| New 6 | 68 (0.2%) | 2 (2.7%) | |
| Graft ischemic time (median hours, IQR) | 3.2 (2.4–3.8) | 3.4 (2.7–3.9) | 0.224 |
| Distance from donor hospital to transplant center (median miles, IQR) | 91 (13–287) | 164 (18–404) | 0.053 |
| Antibody-based induction immunosuppression | 15,177 (50.8%) | 33 (44.0%) | 0.285 |
| Year of transplant (median, IQR) | 2013 (2009–2016) | 2016 (2014–2018) | <0.001 |
| Length of follow up (median years, IQR) | 3.78 (1.05–7.04) | 1.99 (0.56–4.75) | 0.001 |
| IQR, interquartile range; BMI, body mass index; ICU, intensive care unit; IV, intravenous; LVAD, left ventricular assist device; MCS, mechanical circulatory support; IABP, intra-aortic balloon pump; ECMO, extracorporeal membrane oxygenation; VAD, ventricular assist device | |||